ClinicalTrials.gg
RecruitingNCT07225257RETURNUpdated May 28, 2026

Recovery of Physical Function After Critical Illness In Older Adults

An observational study in Sepsis and Acute Lung Injury(ALI), sponsored by University of Kentucky. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by University of Kentucky · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 517 studies in Sepsis with a site in United States — 74 open to participants now, 99 under way, 3 of them phase 3. Sepsis · United States.

Planned enrollment
109th of 204
150 · median 183
Started
2026
with 28 others
Observational
204 of 517
37 open now
Primary completion
2030-06
later than 90 of 98 live
Registered
489th of 517
by date

Among the 517 studies in Sepsis with a site in United States, this one is the 109th largest by planned enrollment of the 204 observational ones that give a count, is one of 29 that started in 2026, is one of 204 observational ones, reaches primary completion later than 90 of the 98 other live ones, and was the 489th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

74 of the 517 studies in Sepsis with a site in United States are open now. Recruiting first, the newest first:

68 more — sign in →

All 74 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 517 studies in Sepsis with a site in United States, or all of them as a file.
02

Study summary

The proposed study is a prospective, observational study assessing the recovery of muscle and physical function in patients surviving critical illness (n =150) at hospital discharge (baseline) and repeated serially. Patients will be enrolled after life-saving modalities have been weaned near hospital discharge. Patients will participate in testing at baseline, 3-, 6-, 12-, and 24-months after hospital discharge. In a subset of patients (n = 18), muscle biopsies will be performed at baseline and then repeated once at either 12- or 24-months after hospital discharge.

Read the detailed description

The overarching goal of the proposed study is to determine the trajectories of physical recovery and cellular markers involved with the underlying failure to recover muscle after critical illness, while exploring which characteristics are associated with sustained physical disability. This proposal will examine muscle pathophysiology carefully aligned with physical function outcomes in order to longitudinally assess the recovery, or failed recovery, of muscle function in participants after critical illness:

Aim 1: Determine the long-term trajectory of muscle strength, physical function and ADL recovery in ICU survivors. Patients (n = 150) will participate in a battery of tests to determine muscle and physical function aligned with self-reported measures of ADLs and quality of life at hospital discharge, 3-, 6-, 12-, and 24-months post.

Aim 2: Assess cellular changes in skeletal muscle in ICU survivors contributing to long-term physical dysfunction. In a subgroup of patients enrolled in Aim 1, muscle biopsies will be collected at baseline and long-term follow-up to determine oxidative stress, mitochondrial function, and cellular senescence.

03

Conditions studied

  • Sepsis
  • Acute Lung Injury(ALI)

Keywords

  • sepsis
  • acute respiratory failure
  • intensive care unit
  • Acquired muscle weakness
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Adults with a diagnosis of acute lung injury or sepsis who have survived an Intensive Care Unit admission for at least 72 hours.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients (≥40 years of age)
  • patients who have survived an ICU admission of at least 72 hours
  • diagnosis of acute lung injury or sepsis are eligible.

Exclusion criteria

Exclusion Criteria:

  • individuals who were not ambulatory prior to ICU admission,
  • not expected to survive at least 6 months,
  • have a new or pre-existing brain infarct, injury, or neurological condition with deficits preventing participation in physical testing,
  • have a pre-existing geriatric syndrome that were confound recovery trajectory
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • RETURN

    Survivors of critical illness

06

What researchers measure

Primary outcomes

  1. Muscle Strength measured by Chair Rise Test

    Performance on 5x sit to stand test will be the primary outcome measure representing lower extremity muscle strength ; measured as time in seconds to complete 5 repetitive sit-stands.

    Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.

  2. Functional Capacity

    The 6-minute walk test (6MWT), which measures the distance a participant can walk in six minutes and serves as an indicator of cardiopulmonary function, will be used as a primary outcome.

    Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.

Secondary outcomes

  1. Muscle morphology # 1

    Myofiber size

    Time frame: Percent change from baseline to 12 months

  2. Muscle morphology #2

    Myofiber type

    Time frame: Percent change from baseline to 12 months

  3. Lower-extremity Muscle Power

    Muscular Power: Power will be assessed using a linear potentiometer (HUMAC-360, CSMi, Stoughton, MA) to record the velocity and peak-velocity of a functional movement using a Shuttle MiniPress (Shuttle Systems, Bellingham, WA) as hamstring/gluteal pressdown. Outcome measure is Watts.

    Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.

  4. Muscle Size and Quality measured by Ultrasound

    Ultrasound imaging will be performed to acquire images of quadriceps and tibialis anterior to measure muscle cross-sectional area, muscle thickness and echo intensity of muscles.

    Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.

  5. Activities of Daily Living (ADL)

    Katz ADL will be used to assess ADL. The range of scores are 0 - 6 with a higher score being an better outcome.

    Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.

  6. Health Reported Quality of Life

    5 Dimension Euro-Quality of Life (EQ-5D) is a self-report instrument including 5 questions and a visual analog scale (0-100) used to measure subjective quality of life with a higher score being a better outcome.

    Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.

  7. Fatigue

    The Functional Assessment of Chronic Illness Therapy (FACIT-fatigue instrument) will be used to measure subjective fatigue and quality of life. All items are summed to create a single score with a range from 0 to 52. Items are reverse scored when appropriate to provide a scale in which higher scores represent better functioning and a higher quality of life.

    Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.

  8. Physical Frailty

    Physical frailty will be quantified using Fried Frailty Phenotype with five criteria (weight loss, weakness, exhaustion, gait speed, and physical activity) and the Clinical Frailty Scale. Scoring is 0-5 with: ≥3/5 criteria met indicates frailty; 1-2/5 indicates pre-or-intermediate frailty; 0/5 indicates non-frail.

    Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.

  9. Physical Activity

    Patients will wear an Actigraph (Garmin, Vivofit 4) or an Oura ring to measure the number of steps per day. The outcome measure will be average number of steps per day over a seven day period.

    Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.

  10. Muscle strength of quadriceps

    Strength of quadriceps muscle will be recorded using a hand-held dynamometry, Lafayette Manual Muscle Test System Model-01165 (Lafayette Company, Lafayette, IN). Outcome is measured in kilograms.

    Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.

  11. Grip Strength

    Hand grip strength will be assessed with a handgrip dynamometry (HGD), Jamar Hydraulic dynamometer (Sammons Preston Rolyan, Bolingbrook, IL, USA). Outcome is measured in kilograms (kgs).

    Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.

  12. Physical function

    The Short Physical Performance Battery (SPPB) assesses balance, repeated sit-to-stand performance, and 4-meter gait speed. Each component is scored and converted to an ordinal scale, with the total score ranging from 0 to 12.

    Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.

  13. Physical function

    Timed-up and Go Test (TUG), which is a measure of mobility and fall risk requiring patients to stand from a chair and walk short-distance for time in seconds.

    Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.

07

Study locations

1 of 1 sites recruiting
  • University of Kentucky, Lexington, Kentucky 40536
    Lexington, Kentucky 40536, United States
    Recruiting
    • Doug A Long, MS · Contactdelong2@uky.edu · 8593231100
    • Kirby P Mayer, DPT, Ph.D. · Principal investigator
    • Esther Dupont-Versteegden, Ph.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided — Not yet decided.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2030, 50 months after the start.

Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 50 months is above that.

Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2025
First posted
Nov 6, 2025
StartActual
Mar 11, 2026
Primary completionEst.
Jun 1, 2030
CompletionEst.
Dec 31, 2031
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07225257
Lead sponsor
University of Kentucky
Responsible party
Kirby Mayer (Associate Professor, University of Kentucky) — Principal investigator
First posted
Nov 6, 2025
Start date
Mar 11, 2026
Primary completion
Jun 1, 2030 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
May 28, 2026

Study contacts

Doug Long, MS
Contact
delong2@uky.edu
859-218-0596
Kirby P Mayer, DPT, Ph.D.
Contact
kpmaye2@uky.edu
859-218-0596
Kirby P Mayer, DPT, Ph.D.
principal investigator · University of Kentucky

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion